June 06, 2023
Alkermes Announces Final Award in Janssen Pharmaceutica Arbitration and Provides Updated Financial Expectations
June 01, 2023
Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc
May 31, 2023
Alkermes to Participate in Two Upcoming Investor Conferences
Alcohol Awareness Month presents an important opportunity to reflect on how we treat people who are living with the condition of Alcohol Use Disorder (AUD). Hear from our Head of Human Resources, Steve Schiavo, on Alkermes' commitment to being a recovery-friendly workplace.
Now in its seventh year, we are proud of the impact the Alkermes Inspiration Grants® program has made in support of creative and innovative programs designed to make a difference for patient communities. Visit the program page to check out a new video highlighting the impact of recent grants.
Alkermes employees work in the laboratory, in the clinic and in the community, seeking to make a positive impact on the lives of people living with complicated and difficult-to-treat diseases. For many of our employees, this work is also part of their personal mission to help improve outcomes for patients, families and communities.
Olanzapine and samidorphan - Schizophrenia or Bipolar I Disorder (pediatric)
ALKS 2680 - Narcolepsy
Nemvaleukin alfa* - Platinum-Resistant Ovarian Cancer
Nemvaleukin alfa - Mucosal Melanoma